Breast Cancer Clinical Trial
Official title:
Impact of Radiofrequency Ablation on Surgical Margins in Early Stage of Malignant Breast Tumors
Background/Main objective: Radiofrequency ablation (RFA) is a minimally invasive procedure
widespread accepted in the treatment of different tumors, especially in the liver but its
benefit is not yet well-known in breast cancer.
Our main objective is to evaluate the usefulness of RFA in < 2cm malignant breast tumors to
reduce the proportion of positive margins.
Methodology: The investigator propose a single-center, single-blind, phase I and II
randomized controlled trial. Phase I:Security of the cool-tip cluster electrode assessing the
potential adverse effects in three stages: initial,intermediate and final. Phase II:
Randomized clinical trial, 2 parallel groups with 37 patients in each one.
Experimental group: percutaneous RFA previous to conventional lumpectomy. Control group:
conventional surgery with lumpectomy. The number of positive margins in both groups, and the
need of extending margin resection will be assessed intraoperatively. Inclusion criteria:
women >40 years, infiltrating ductal breast carcinoma by biopsy. The tumor must be unique,
visible by ultrasound, smaller than 2cm and located > 1 cm from the chest wall and the skin.
Patients will be followed up for a period of two years to assess cosmetic result, short -term
and long -term complications and recurrences.
Expected results: The "cool-tip" (cluster) ablation method reduces by at least 30% the risk
of intraoperative extensions for positive margins during lumpectomy compared to conventional
surgery in breast tumors with a diameter < 2 cm.
Therefore this procedure may reduce the risk of second surgeries and the removed volume of
tissue.Consequently the final cosmetic result should be improved.
Main objectives of the project:
- To evaluate the usefulness of radiofrequency ablation (RFA) to achieve a lower
percentage of positive margins.
- To validate clinically the efficacy and safety of the method in breast tumors smaller
than < 2 cm.
Specific objectives of the project:
1. To demonstrate that , after RFA, clear margins are increased in the intraoperative
pathological analysis compared to conventional surgery.
1. To quantify the number of positive margins requiring intraoperative extension in
each patient, comparing the ratio in both groups.
2. To quantify the percentage of patients requiring intraoperative extension compared
in both groups.
2. To demonstrate a reduction in the volume of breast tissue removed after RFA compared to
conventional surgery.
1. Comparing in both groups the anteroposterior, transverse and craniocaudal diameters
of the excised specimen, measured in cm, and to calculate the volume.
2. Tumor weight in grams (including extensions) will be measured to compare the
weights in both groups.
3. To evaluate the differences in cosmetic outcome after RFA versus conventional surgery.
a. An international scale will be used and the scores will be compared. There will be
two independent assessments, one for the physician and another for the patient.
4. To demonstrate the effectiveness of the RFA by cluster "cool-tip" electrode in the
experimental group.
1. RFA is considered as complete when no viable tumor tissue is evidenced by
oxidation-reduction reaction mediated by NADH-diaphorase after surgical resection.
Mitochondrial dysfunction will be also evaluated by semiquantitative and
quantitative method using the enzyme cytochrome c oxidase or Complex IV (COX) and
tunel. Any residual viable tumor tissue will be considered as incomplete RFA.
2. Risk factors for incomplete ablations will be analyzed, especially tumor
vascularization.
5. To demonstrate the safety of RFA by cluster "cool-tip" electrode in breast cancer tumors
a. To quantify all side effects that may occur after the RFA and / or surgery and to
correlate the complication rate in each group with severity.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
Recruiting |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
Recruiting |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A |